Clinical Oncology Articles & Analysis: Older
120 news found
Tempus is now offering these two IHC tests, which are recommended in clinical guidelines for several cancer types and may be ordered for other cancer types at the clinician’s discretion. ...
ByTempus
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various types of metastatic disease burden and risk, compared to ADT with docetaxel alone Favorable safety profile of darolutamide plus ...
ByBayer AG
Mulinacci added, “I look forward to working with the team at Araris to expand on its business development efforts as they further advance their oncology pipeline of next-generation antibody-drug conjugates (ADCs) into the clinic. ...
The strategic transaction also adds significant tailwinds behind Inspirata’s ongoing focus to become the leading provider of cloud-based, enterprise software as a service (SaaS) solutions for Oncology Informatics – its main strategic pillar of growth. Critical workflows in Oncology Informatics, such as clinical trial matching and ...
Novartis obtains exclusive worldwide rights for pre-clinical inhibitors of a novel cancer target MorphoSys receives an upfront payment of $23 million, potential milestone payments, plus mid-single- to low-double-digit royalties on net sales MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its fully owned subsidiary Constellation Pharmaceuticals, Inc. has entered ...
The combination of existing IP and expertise in areas such as genomic data management, variant interpretation, NGS data quality control, and precision oncology, was fundamental to the partnership being awarded the contract. Kurt Zatloukal, Professor of Pathology at the Medical University Graz, said, “Phase one of this important project to deliver innovative NGS workflows, ...
(Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. ...
Initial results of the TORCH-2 study were presented at the 2022 American Society of Clinical Oncology (ASCO 2022) Annual Meeting. About the TORCH Trial The TORCH trial was designed as a multi-regional clinical trial to evaluate the pharmacokinetics, safety, tolerability and efficacy of oral ATG-008 in hepatitis B positive (HBV+) hepatocellular ...
In addition to their outstanding clinical research in oncology, Peter Mac through Cell Therapies Pty Ltd has substantial experience in manufacturing of cell therapies for cancer.” The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. ...
Proceeds and cost-savings from the divestiture of the CDMO facility and reduction in operations will be invested in advancing the Company’s lead immuno-oncology assets towards the clinic, as well as the continued development of the RubrYc® Discovery Engine, the artificial intelligence (“AI”) platform used to create the majority of ...
CST on December 10, 2022. Dr. Meshinchi is Professor, Clinical Research Division, at Fred Hutchinson Cancer Research Center and Professor, Division of Pediatric Hematology-Oncology, at the University of Washington School of Medicine. ...
(Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. ...
To date, multiple XPOVIO® regimens have been added to the clinical guidelines of major oncology societies in the U.S., the EU, and APAC, including 5 regimens for the treatment of myeloma and 1 regimen for the treatment of lymphoma added to the guidelines of the National Cancer Care Network (NCCN); 4 regimens for the treatment of myeloma and 1 regimen for the ...
This unique public-private partnership between an innovative NHS organisaiton and a world leading cancer theranostic company is breaking down a significant barrier to biomarker testing helping clinical colleagues more easily personalise care for patients with cancer”. DR NADINE COLLINS, CONSULTANT CLINICAL SCIENTIST IN MOLECULAR DIAGNOSTICS WHO IS BASED AT ...
Effective October 3rd, 2022, Laurie Smith has joined as Vice President of Product Strategy – Clinical Trial Matching. Laurie will be primarily focused on enhancing Inspirata’s suite of clinical trial matching solutions. ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in ...
The financing round is completed by non-dilutive financing, in the form of a grant and debt from BPIFrance and the EIC accelerator. On the way to clinical trials The first objective of this financing round is the completion of the pre-market clinical evaluation of the MATTISSE implant. The clinical trial, started in July 2022 and plans to ...
After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the ...
Results from the primary analysis of the SUNLIGHT trial to be presented at an upcoming scientific conference Paris - September 12, 2022– Servier, Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd., announced today that the investigational combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in the primary endpoint of ...
(Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ...